Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN)
Standard
Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). / Hepatitis Delta International Network.
In: LIVER INT, Vol. 38, No. 5, 05.2018, p. 842-850.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN)
AU - Wranke, Anika
AU - Pinheiro Borzacov, Lourdes M
AU - Parana, Raymundo
AU - Lobato, Cirley
AU - Hamid, Saeed
AU - Ceausu, Emanoil
AU - Dalekos, George N
AU - Rizzetto, Mario
AU - Turcanu, Adela
AU - Niro, Grazia A
AU - Lubna, Farheen
AU - Abbas, Minaam
AU - Ingiliz, Patrick
AU - Buti, Maria
AU - Ferenci, Peter
AU - Vanwolleghem, Thomas
AU - Hayden, Tonya
AU - Dashdorj, Naranjargal
AU - Motoc, Adriana
AU - Cornberg, Markus
AU - Abbas, Zaigham
AU - Yurdaydin, Cihan
AU - Manns, Michael P
AU - Wedemeyer, Heiner
AU - Hardtke, Svenja
AU - Hepatitis Delta International Network
N1 - © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2018/5
Y1 - 2018/5
N2 - BACKGROUND & AIMS: Chronic hepatitis D (delta) is a major global health burden. Clinical and virological characteristics of patients with hepatitis D virus (HDV) infection and treatment approaches in different regions world-wide are poorly defined.METHODS: The Hepatitis Delta International Network (HDIN) registry was established in 2011 with centres in Europe, Asia, North- and South America. Here, we report on clinical/ virological characteristics of the first 1576 patients with ongoing or past HDV infection included in the database until October 2016 and performed a retrospective outcome analysis. The primary aim was to investigate if the region of origin was associated with HDV replication and clinical outcome.RESULTS: The majority of patients was male (n = 979, 62%) and the mean age was 36.7 years (range 1-79, with 9% of patients younger than 20 years). Most patients were HBeAg-negative (77%) and HDV-RNA positive (85%). Cirrhosis was reported in 48.7% of cases which included 13% of patients with previous or ongoing liver decompensation. Hepatocellular carcinoma (HCC) developed in 30 patients (2.5%) and 44 (3.6%) underwent liver transplantation. Regions of origin were independently associated with clinical endpoints and detectability of HDV RNA. Antiviral therapy was administered to 356 patients with different treatment uptakes in different regions. Of these, 264 patients were treated with interferon-a and 92 were treated with HBV-Nucs only.CONCLUSIONS: The HDIN registry confirms the severity of hepatitis delta but also highlights the heterogeneity of patient characteristics and clinical outcomes in different regions. There is an urgent need for novel treatment options for HDV infection.
AB - BACKGROUND & AIMS: Chronic hepatitis D (delta) is a major global health burden. Clinical and virological characteristics of patients with hepatitis D virus (HDV) infection and treatment approaches in different regions world-wide are poorly defined.METHODS: The Hepatitis Delta International Network (HDIN) registry was established in 2011 with centres in Europe, Asia, North- and South America. Here, we report on clinical/ virological characteristics of the first 1576 patients with ongoing or past HDV infection included in the database until October 2016 and performed a retrospective outcome analysis. The primary aim was to investigate if the region of origin was associated with HDV replication and clinical outcome.RESULTS: The majority of patients was male (n = 979, 62%) and the mean age was 36.7 years (range 1-79, with 9% of patients younger than 20 years). Most patients were HBeAg-negative (77%) and HDV-RNA positive (85%). Cirrhosis was reported in 48.7% of cases which included 13% of patients with previous or ongoing liver decompensation. Hepatocellular carcinoma (HCC) developed in 30 patients (2.5%) and 44 (3.6%) underwent liver transplantation. Regions of origin were independently associated with clinical endpoints and detectability of HDV RNA. Antiviral therapy was administered to 356 patients with different treatment uptakes in different regions. Of these, 264 patients were treated with interferon-a and 92 were treated with HBV-Nucs only.CONCLUSIONS: The HDIN registry confirms the severity of hepatitis delta but also highlights the heterogeneity of patient characteristics and clinical outcomes in different regions. There is an urgent need for novel treatment options for HDV infection.
KW - Adolescent
KW - Adult
KW - Aged
KW - Antiviral Agents/administration & dosage
KW - Carcinoma, Hepatocellular/epidemiology
KW - Child
KW - Child, Preschool
KW - Cross-Sectional Studies
KW - Female
KW - Genetic Heterogeneity
KW - Hepatitis B Surface Antigens/blood
KW - Hepatitis D/complications
KW - Hepatitis Delta Virus/genetics
KW - Humans
KW - Infant
KW - Internationality
KW - Liver/pathology
KW - Liver Cirrhosis/epidemiology
KW - Liver Neoplasms/epidemiology
KW - Liver Transplantation
KW - Logistic Models
KW - Male
KW - Middle Aged
KW - Registries
KW - Retrospective Studies
KW - Young Adult
U2 - 10.1111/liv.13604
DO - 10.1111/liv.13604
M3 - SCORING: Journal article
C2 - 28963781
VL - 38
SP - 842
EP - 850
JO - LIVER INT
JF - LIVER INT
SN - 1478-3223
IS - 5
ER -
